ARO-INHBE
Low EvidenceAn investigational RNA-interference (RNAi) therapeutic from Arrowhead Pharmaceuticals designed to treat obesity by silencing a fat-storage gene in the liver. ARO-INHBE is a GalNAc-conjugated small interfering RNA (siRNA) that reduces hepatic expression of the INHBE gene and its secreted product, the hepatokine Activin E. INHBE is a genetically validated target: people who naturally carry rare loss-of-function variants in INHBE have a healthier (less abdominal) fat distribution and a lower risk of type 2 diabetes, suggesting that lowering Activin E with a drug could reproduce that protective metabolic profile. In an ongoing Phase 1/2a trial (AROINHBE-1001, NCT06700538), a single subcutaneous dose reduced serum Activin E by up to about 94%, and monotherapy reduced visceral fat by roughly 10-16% while modestly increasing lean tissue. Most strikingly, when added to the incretin drug tirzepatide in obese patients with type 2 diabetes, ARO-INHBE roughly doubled weight loss (-9.4% versus -4.8% at week 16) and roughly tripled reductions in visceral, total, and liver fat versus tirzepatide alone. These are small, early, interim results (as few as 3-4 participants per combination arm) - not proof of durable or long-term benefit. ARO-INHBE is investigational, is not approved anywhere, and is not a supplement or research chemical; it is studied only in clinical trials.
What It Is
ARO-INHBE is an investigational RNA-interference (RNAi) medicine from Arrowhead Pharmaceuticals (NASDAQ: ARWR), built on the company's Targeted RNAi Molecule (TRiM) platform and conjugated to N-acetylgalactosamine (GalNAc) so that it is taken up efficiently by liver cells. Once inside hepatocytes, the small interfering RNA (siRNA) engages the cell's natural gene-silencing machinery (the RNA-induced silencing complex) to degrade the messenger RNA of the INHBE gene, cutting production of its secreted protein, the hepatokine Activin E. The rationale is unusually well grounded in human genetics: large exome-sequencing studies of roughly 362,679 people (published in Nature Communications in 2022) found that rare predicted loss-of-function variants in INHBE are associated with a lower waist-to-hip ratio adjusted for BMI - that is, a healthier, less abdominal pattern of fat - together with about 28% lower odds of type 2 diabetes and a favorable metabolic profile (lower triglycerides, higher HDL cholesterol, and lower fasting glucose). The most common loss-of-function variant reduces secreted Activin E by around 90%, so a drug that lowers Activin E is essentially trying to mimic a naturally protective human genotype. Activin E is thought to act as a ligand in a signaling pathway - closely tied to the adipocyte receptor ALK7 (encoded by ACVR1C) - that regulates energy storage in fat tissue; lowering it is proposed to increase fat breakdown (lipolysis) and reduce adipose hypertrophy, visceral adiposity, and insulin resistance. Arrowhead is developing ARO-INHBE alongside a companion siRNA, ARO-ALK7, that silences ACVR1C directly inside fat cells. In a first-in-human Phase 1/2a study, ARO-ALK7 became the first RNAi therapeutic reported to knock down an adipocyte-expressed gene in people, achieving a mean reduction of about 88% (maximum about 94%) in ALK7 messenger RNA and a placebo-adjusted visceral-fat reduction of about 14.1% by week 8 after a single dose. For ARO-INHBE itself, the AROINHBE-1001 trial (NCT06700538) is a dose-escalating Phase 1/2a study in up to 78 adults with obesity, with Part 1 testing single and multiple monotherapy doses and Part 2 testing ARO-INHBE added to tirzepatide, the approved GLP-1/GIP receptor co-agonist. Interim results announced in January 2026 were striking. A single subcutaneous dose reduced serum Activin E dose-dependently, with a mean maximum reduction of about 85% after a 400 mg dose and a maximum observed reduction of about 94%. As monotherapy, a single dose reduced visceral fat by about 9.9% and liver fat by about 38% and increased total lean tissue by about 3.6% at week 16, and two doses reduced visceral fat by about 15.6% (placebo-adjusted) at week 24. In combination, two doses of ARO-INHBE (400 mg) added to tirzepatide (n=4) produced roughly a two-fold greater weight loss at week 16 (-9.4% versus -4.8% for tirzepatide plus placebo, n=5) and roughly a three-fold greater reduction in fat on week-12 MRI: visceral fat -23.2% versus -7.4%, total fat -15.4% versus -5.3%, and relative liver-fat reduction -76.7% versus -20%. Early safety was described as generally well tolerated: most treatment-emergent adverse events were mild, gastrointestinal event rates were similar to tirzepatide alone, injection-site reactions were generally mild and self-limited, and no adverse events led to discontinuation; one serious adverse event (a limb abscess, managed with drainage) was judged unrelated to study treatment. The strategic pitch is that incretin drugs, for all their success, still leave problems - loss of lean mass, gastrointestinal tolerability, a weaker response in people with type 2 diabetes, and disproportionate fat regain after stopping - and that silencing a fat-storage hepatokine may selectively strip visceral and liver fat while preserving muscle, either on its own or stacked on an incretin. The important caveats are large: these are interim, early-phase results from very small numbers of participants (as few as 3-4 per combination arm), the eye-catching two-to-three-fold improvements are signals rather than proven clinical benefits, no Phase 3 program has reported, and the long-term safety of chronically lowering Activin E is unknown. ARO-INHBE has no regulatory approval anywhere, is not a supplement or research chemical, and any product sold under its name outside a regulated clinical trial is unverified and unsafe.
Regulatory Status
Not approved by the FDA, EMA or any regulator. ARO-INHBE is an investigational GalNAc-conjugated INHBE siRNA (RNA-interference therapeutic) in clinical development by Arrowhead Pharmaceuticals for obesity and metabolic disease. It is in a Phase 1/2a dose-escalating trial (AROINHBE-1001, NCT06700538), with interim data reported in January 2026 showing deep Activin E knockdown and substantial visceral, total and liver fat reduction (alone and added to tirzepatide). Available only within clinical trials; no Phase 3 program has reported.
Effective: 2026
View FDA SourceWhy Researchers Study It
ARO-INHBE is one of the first real tests of a compelling idea: that human genetics can point directly at a drug target for obesity. Rather than suppressing appetite through gut-hormone signaling, ARO-INHBE tries to copy a naturally protective genotype - people born with rare loss-of-function variants in the INHBE gene carry less abdominal fat, have a healthier metabolic profile, and are markedly less likely to develop type 2 diabetes. Because that experiment has, in effect, already been run in nature, lowering the INHBE product Activin E is an unusually well de-risked hypothesis, and RNA interference is a natural tool to test it: a GalNAc-conjugated siRNA can achieve deep, durable knockdown of a liver gene with infrequent injections. Researchers are also drawn to ARO-INHBE because it targets the specific shortcomings of incretin drugs. GLP-1 and GLP-1/GIP medicines produce large weight loss but also cost patients lean muscle, cause gastrointestinal side effects, work less well in people with diabetes, and are followed by disproportionate fat regain when stopped - so a therapy that selectively reduces visceral and liver fat while preserving muscle, either alone or stacked on tirzepatide, would be genuinely additive. Early interim data made that case vividly, with roughly doubled weight loss and tripled fat reduction on top of tirzepatide and a small gain in lean tissue on monotherapy. The program is equally interesting for what it reveals about human biology: its companion siRNA ARO-ALK7 was reported as the first RNAi therapeutic to silence an adipocyte-expressed gene in people, opening the broader Activin E/ALK7 fat-storage pathway to direct study. The honest caveat is that all of this rests on very small, interim, early-phase numbers, so researchers watch ARO-INHBE both for its promise and as a test of whether a genetics-first, RNAi-based approach to body composition holds up in larger, longer trials.
Proposed Mechanisms
- INHBE gene silencing via RNA interference: ARO-INHBE is a GalNAc-conjugated small interfering RNA (siRNA) taken up by liver hepatocytes, where it engages the RNA-induced silencing complex to degrade INHBE messenger RNA and reduce production of the secreted hepatokine Activin E (serum Activin E fell by up to about 94% after a single dose in early trials).
- Lowering Activin E signaling: Activin E is thought to act as a ligand - closely linked to the adipocyte receptor ALK7 (ACVR1C) - in a pathway that promotes fat storage and restrains fat breakdown; reducing it is proposed to increase lipolysis and reduce adipose hypertrophy, adipose dysfunction, visceral adiposity, and insulin resistance.
- Preferential visceral and liver fat reduction: in early trials, Activin E knockdown was associated with disproportionate reductions in visceral fat and liver fat and, as monotherapy, a small increase in lean tissue - a body-composition profile distinct from the primarily calorie- and appetite-driven weight loss of incretin drugs.
- Genetic validation as a mechanistic anchor: humans carrying rare loss-of-function INHBE variants have a lower waist-to-hip ratio (favorable fat distribution) and roughly 28% lower odds of type 2 diabetes, providing a natural human model that lowering Activin E is metabolically beneficial and likely tolerable.
- Complementarity with incretins and a companion pathway drug: because it works through fat-storage biology rather than gut-hormone appetite signaling, ARO-INHBE is being tested on top of tirzepatide - where it roughly doubled weight loss and tripled fat reduction in interim data - and a companion siRNA, ARO-ALK7, silences the adipocyte receptor ACVR1C in the same Activin E/ALK7 axis.
Evidence Snapshot
| Study Type | Model | Outcome | Link |
|---|---|---|---|
| Human genetics: multiancestry exome-sequencing association studies (target validation) | Exome sequences from roughly 362,679 individuals analyzed for waist-to-hip ratio adjusted for BMI (a surrogate for abdominal fat), with functional characterization of INHBE predicted loss-of-function variants; published in Nature Communications (2022). | Rare loss-of-function variants in INHBE (encoding the hepatokine Activin E) were associated with lower abdominal fat (favorable fat distribution) and roughly 28% lower odds of type 2 diabetes, with a favorable metabolic profile (lower triglycerides, higher HDL, lower fasting glucose); the common variant reduces secreted Activin E by about 90% - validating INHBE/Activin E as a therapeutic target for abdominal obesity. | Source |
| Phase 1/2a randomized, dose-escalating trial - ARO-INHBE monotherapy (AROINHBE-1001, NCT06700538); interim data January 2026 | Adults with obesity given single or multiple subcutaneous doses of ARO-INHBE versus placebo (about 4 per dose level), with measurement of serum Activin E, visceral and liver fat by MRI, and lean tissue. | A single dose reduced serum Activin E dose-dependently (mean maximum -85% after 400 mg; maximum observed -94%). At week 16, single-dose monotherapy reduced visceral fat by about 9.9% and liver fat by about 38% and increased total lean tissue by about 3.6%; two doses reduced visceral fat by about 15.6% (placebo-adjusted) at week 24. | Source |
| Phase 1/2a combination - ARO-INHBE plus tirzepatide versus tirzepatide alone (AROINHBE-1001, Part 2); interim data January 2026 | Obese patients with type 2 diabetes given ARO-INHBE 400 mg plus tirzepatide (n=4) versus tirzepatide plus placebo (n=5); mean percent change from baseline in weight (week 16) and in fat by MRI (week 12). | Adding ARO-INHBE roughly doubled weight loss (-9.4% versus -4.8%) and roughly tripled fat reductions - visceral fat -23.2% versus -7.4%, total fat -15.4% versus -5.3%, and relative liver-fat reduction -76.7% versus -20% - versus tirzepatide alone, with a generally well-tolerated early safety profile (very small numbers; interim data). | Source |
Commonly Discussed Benefits
Researching ARO-INHBE? Track it, set reminders, and keep notes in the free app.
Safety & Cautions
- ARO-INHBE is an investigational medicine with no regulatory approval anywhere; it is not a supplement or research chemical, and any product sold as 'ARO-INHBE', 'INHBE siRNA' or 'Activin E siRNA' outside a regulated clinical trial is unverified and unsafe.
- Human data are very early and come from tiny numbers of participants (as few as 3-4 per combination arm); the striking two-to-three-fold improvements are interim signals, not proven or durable clinical benefits, and no Phase 3 trial has reported.
- The long-term safety of chronically lowering Activin E and disrupting the Activin E/ALK7 fat-storage pathway is unknown; this pathway influences metabolism broadly, and unanticipated effects cannot be excluded from short, small studies.
- Early safety looked clean (mostly mild adverse events, gastrointestinal rates similar to tirzepatide alone, and one serious adverse event - a limb abscess - judged unrelated to treatment), but injection-site reactions and other class effects of GalNAc siRNAs require much longer follow-up.
- Much of the headline efficacy comes from combination with tirzepatide, a prescription GLP-1/GIP incretin drug; the added benefit and safety of stacking an experimental siRNA on an approved incretin are not established.
- Decisions about obesity, diabetes or metabolic treatment should be made with a qualified clinician; this is background information about an experimental medicine, not medical advice, and ARO-INHBE is available only through clinical trials.
Comparisons
See how ARO-INHBE compares to related peptides:
Calculator Tools
Use our research tools to explore dosing and reconstitution data:
Citations
- [1] Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates (ARO-INHBE and ARO-ALK7) - Arrowhead Investor Relations (January 6, 2026) PubMed
- [2] Arrowhead Pharmaceuticals Announces Interim Clinical Data on RNAi-based Obesity Candidates - Business Wire (January 6, 2026) PubMed
- [3] RNAi-based therapeutics could treat obesity, results show - Drug Discovery World (January 7, 2026) PubMed
- [4] AROINHBE-1001: A Study of ARO-INHBE in Adult Participants With Obesity - ClinicalTrials.gov (NCT06700538) PubMed
- [5] AROALK7-1001: A Study of ARO-ALK7 in Adult Participants With Obesity - ClinicalTrials.gov (NCT06937203) PubMed
- [6] Deaton AM, et al. Rare loss of function variants in the hepatokine gene INHBE protect from abdominal obesity - Nature Communications (2022) PubMed
- [7] Akbari P, et al. Multiancestry exome sequencing reveals INHBE mutations associated with favorable fat distribution and protection from diabetes - Nature Communications (2022) PubMed
Keep researching in the app
- Log ARO-INHBE to your private tracker
- Set a dosing reminder
- Compare it side-by-side with your stack
Related Peptides
Bimagrumab
Medium EvidenceAn anti-activin type II receptor antibody that promotes fat loss while preserving lean muscle mass, studied in combination with GLP-1 agonists for obesity.
Plozasiran
High EvidenceAn approved subcutaneous RNA interference (RNAi) therapy from Arrowhead Pharmaceuticals, branded Redemplo, that silences the gene for apolipoprotein C-III (apoC-III) to lower triglycerides. Given once every three months, it cut triglycerides by roughly 80% in familial chylomicronemia syndrome (FCS) and sharply reduced acute pancreatitis events. The FDA approved it on November 18, 2025 for FCS, and Phase 3 SHASTA-3 and SHASTA-4 (reported July 2026) extended those results to the far larger severe hypertriglyceridemia population.
Retatrutide
High EvidenceAn investigational triple agonist (GIP/GLP-1/glucagon) studied for obesity and metabolic disease.
Tirzepatide
High EvidenceA dual GIP/GLP-1 receptor agonist FDA-approved for type 2 diabetes, weight management, and MASH with liver fibrosis.
Zilebesiran
Medium EvidenceAn investigational subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Alnylam Pharmaceuticals and Roche/Genentech that lowers blood pressure by silencing angiotensinogen (AGT), the single upstream precursor of the renin-angiotensin-aldosterone system (RAAS). Designed for dosing as infrequently as once or twice a year, it is the first RNА interference (RNAi) therapeutic developed for hypertension. In Phase 2 KARDIA-1 and KARDIA-2 trials it produced durable, clinically meaningful reductions in systolic blood pressure sustained for up to 6 months from a single dose, and in 2025 it advanced into the large Phase 3 ZENITH cardiovascular outcomes trial.
Zodasiran
Medium EvidenceAn investigational subcutaneous GalNAc-conjugated small interfering RNA (siRNA) from Arrowhead Pharmaceuticals that lowers atherogenic lipids by silencing ANGPTL3 (angiopoietin-like protein 3), a liver-made regulator of fat metabolism. By switching off ANGPTL3 production, zodasiran deeply reduces triglycerides, remnant cholesterol and LDL cholesterol through a pathway that does not depend on the LDL receptor - making it especially relevant for people, such as those with homozygous familial hypercholesterolemia (HoFH), whose LDL receptors barely work. In the Phase 2b ARCHES-2 trial (NEJM 2024) it produced durable, dose-dependent reductions in triglycerides, remnant cholesterol and ANGPTL3, and in the Phase 2 GATEWAY study it lowered LDL cholesterol by about 40% in HoFH. It is now in the Phase 3 YOSEMITE trial in HoFH, which completed enrollment in July 2026.